Full text loading...
- ISSN: 1871-529X
- E-ISSN: 2212-4063
-
Clinical Post-Transplant Lymphoproliferative Disorders
- Source: Cardiovascular & Haematological Disorders - Drug Targets, Volume 22, Issue 2, Jun 2022, p. 96 - 103
-
- 01 Jun 2022
Abstract
Post-transplant lymphoproliferative disorders (PTLDs) are characterized by hyperproliferation of B cells due to solid organ or allogeneic hematopoietic stem cell transplant. Based on histological findings, it is divided into 4 categories. Most PTLD patients are Epstein–Barr virus (EBV) positive. Additionally, aggressive immunosuppressive therapies can also lead to PTLD. Reducing immunosuppressive regimes, antivirals, monoclonal antibodies, chemotherapy, and radiotherapy are available therapeutic options, depending on the nature and phase of the disease. This review briefly highlights pathogenesis, risk factors, prevention, and therapeutic strategies regarding PTLDs.
© Bentham Science Publishers